Fulcrum Therapeutics, Inc.
FULC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680581
In the last 90 days, Fulcrum Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 154 institutions reported holding it in 13F filings for Q2 2026, worth $291.3M in total; no superinvestor holds it.
Holders of 5% or more of FULC
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Fulcrum Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13G/A | 9.90%6.65M shares | −1.30 ppfrom 11.20% | Dec 10, 20252 filings | Feb 17, 2026 | SEC |
| Suvretta Capital Management, LLC | 13G/A | 9.40%5.07M shares | +3.10 ppfrom 6.30% | Jan 6, 20252 filings | May 2, 2025 | SEC |
| EcoR1 Capital, LLC | 13G | 9.00%6.00M shares | 0.00 ppfrom 9.00% | Jun 25, 20262 filings | Jun 25, 2026 | SEC |
| Tang Capital Management LLC | 13G | 8.20%5.45M shares | New | Jun 10, 20261 filing | Jun 10, 2026 | SEC |
| TCG Crossover GP II, LLC | 13G/A | 7.90%5.25M shares | – | May 15, 20261 filing | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.00%3.27M shares | −1.50 ppfrom 7.50% | Apr 17, 20252 filings | Oct 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
16 Schedule 13D and 13G filings on Fulcrum Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 25, 20266:10 PM ET | EcoR1 Capital, LLCand 2 others | 13G | 9.00%6.00M shares | 0.00 ppfrom 9.00% | Jun 17, 2026 | SEC |
| Jun 25, 20265:51 PM ET | EcoR1 Capital, LLCand 2 others | 13G | 9.00%6.00M shares | New | Jun 17, 2026 | SEC |
| Jun 10, 20266:13 PM ET | Tang Capital Management LLCand 5 others | 13G | 8.20%5.45M shares | New | Jun 3, 2026 | SEC |
| May 15, 20264:36 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 4.58%3.05M shares | −3.08 ppfrom 7.66%Below 5% | Mar 31, 2026 | SEC |
| May 15, 20264:26 PM ET | TCG Crossover GP II, LLCand 2 others | 13G/A | 7.90%5.25M shares | – | Mar 31, 2026 | SEC |
| Mar 26, 20266:37 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20264:29 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%6.65M shares | −1.30 ppfrom 11.20% | Dec 31, 2025 | SEC |
| Dec 10, 20254:44 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 11.20%6.05M shares | – | Dec 8, 2025 | SEC |
| Nov 13, 20259:03 AM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 4.50%2.43M shares | −4.00 ppfrom 8.50%Below 5% | Sep 30, 2025 | SEC |
| Oct 17, 20256:40 PM ET | BlackRock, Inc. | 13G/A | 6.00%3.27M shares | −1.50 ppfrom 7.50% | Sep 30, 2025 | SEC |
| Aug 12, 20259:01 AM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 8.50%4.59M shares | +2.94 ppfrom 5.56% | Jun 30, 2025 | SEC |
| May 2, 20255:33 PM ET | Suvretta Capital Management, LLCand 2 others | 13G/A | 9.40%5.07M shares | +3.10 ppfrom 6.30% | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 7.50%4.03M shares | – | Mar 31, 2025 | SEC |
| Feb 12, 20259:32 AM ET | Adage Capital Management, L.P.and 2 others | 13G | 5.56%3.00M shares | New | Dec 31, 2024 | SEC |
| Jan 6, 20254:50 PM ET | Suvretta Capital Management, LLCand 2 others | 13G | 6.30%3.40M shares | New | Dec 27, 2024 | SEC |
| Nov 14, 20244:53 PM ET | Nantahala Capital Management, LLCand 2 others | 13G | 7.66%4.78M shares | New | Sep 30, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Fulcrum Therapeutics, Inc. shares.
No Form 144 notices for Fulcrum Therapeutics, Inc. are on file.